2022 ESMO Chinese scholars' oral report list is hot!17 studies were successfully shortlisted!

*For medical professionals for reading reference

Tissue blood tidelle!

The most prestigious and influential oncology conference in Europe, the European Cancer Internal Science Society (ESMO) Annual Conference will arrive in September, this conference time is from September 9th to September 13th (Central EU Summer Time time To.

The editor of the medical circles of tumor channels compiled the theme of Chinese speakers reported by the Proffered Paper Session and MINI Oral SESSION. Not much to say, let's take a look at the 2022 ESMO Annual Meeting. What are the "Voice of China" worthy of attention? (The following rankings are not distinguished, please forgive me if there are omissions, please leave a message to add)

Lung cancer

1. Specialty: mini oral session: nsclc, metastatic

Title: SUNRISE: Cyli Mipide+Arotinib vs Platinum is the basal chemotherapy first -line therapy metastatic non -small cell lung cancer (NSCLC), an open label, center, and random II clinical study

Summary number: LBA57

Reporter: Han Baohui Shanghai Chest Hospital

Original title: Sintilimab Plus Anlotinib Versus Platinum-Based Chemotherapy As First-Line therapy In Metastatic NSCLC (Sunrise): An Open Label, Multi-CENTER, RANDINED, PHASE 2 Studem

2. Specialty: mini oral session: nsclc, metastatic

Title: Orient-31 Phase III Clinical Research Second Intermediate Analysis: Shindi Mipide ± IBI305+chemotherapy therapy EGFR-TKI treated EGFR mutant non-scale NSCLC efficacy

Summary number: LBA58

Reporter: Lu Shun Shanghai Chest Hospital

Sintilimab with or without IBI305 plus chemotherapy in patients with EGFR mutated non-squamous non-small-cell lung cancer (EGFRm nsqNSCLC) who progressed on EGFR tyrosine-kinase inhibitors (TKIs) therapy: second interim analysis of phase 3 ORIENT-31 study

3. Specialty: Proffered Paper Session: Non-Metastatic NSCLC and Other Thoracic Malignannacies

Title: Guangzhou community through low -dose spiral CT screening lung cancer condition

Summary number: LBA48

Reporter: Liang Wenhua First Affiliated Hospital of Guangzhou Medical University

Original title: Commith-Based Mass Screening with Low-Dose CT for LUNG CANCER in Guangzhou

4. Special: Mini Oral Session: Basic Science Translational Research

Title: Classification of Pulmonary Nodules of Comprehensive Clinical, Image, DNA methylized biomarkers

Summary number: 905mo

Reporter: Liang Wenhua First Affiliated Hospital of Guangzhou Medical University

Original title: Synergistical of Clinical, Imaging and DNA METHYLATION BIOMARKERS IMPROVES the Classification of Pulmonary Nodules

Breast cancer

5. Specialty: Proffered Paper Session: Breast Cancer, Metastatic

Title: Phase III Clinical Studies: Dalacille+Benzole/Anatonazo first-line therapy HR+/HER2-advanced breast cancer

Summary number: LBA16

Reporter: Xu Binghe Academy of Medical Sciences Cancer Hospital

Original title: DalPiciclib Plus Letrozole or Anastrozole As 1st-Line Treatment for HR+/HER2-Advanced Breast Cancer (DAWNA-2): A Phase 3 TRIAL

6. Specialty: Mini Oral Session: Breast Cancer, Metastative Title: Phila: Phase III clinical research explores piestinib or placebo combined with Topo Ming+Dorthecie Treatment HER2 -positive mammary breast cancer

Summary number: LBA19

Reporter: Xu Binghe Academy of Medical Sciences Cancer Hospital

Original title: Pyrotinib or Placebo in Combination with Trastuzumab and Docetaxel for Her2-POSITIVE METASTASTASTAST CANCER (Phila): A Randomize 3 TRIAL

Digestive system tumor

7. Special: MINI ORAL Session: GI, Upper Digestive

Title: HR070803+5-FU/LV VS placebo+5-FU/LV second-line therapy for local advanced/metastatic pancreatic cancer: a multi-center, random, double-blind, parallel control phase III clinical research (HR -Iri-APC)

Summary number: LBA61

Reporter: Wang Liwei Shanghai Jiaotong University Affiliated to Renji Hospital

原标题：HR070803 plus 5-FU/LV versus placebo plus 5-FU/LV in second-line therapy for gemcitabine-refractory locally advanced or metastatic pancreatic cancer: a multicentered, randomized, double-blind, parallel-controlled phase III trial ( HR-IRI-APC)

8. Special: Mini Oral Session: Investigational Immunotherapy

Title: targeted EPCAM CAR-T cell therapy to treat advanced colorectal cancer and advanced gastric cancer

Summary number: 737mo

Reporter: Fang Weijia First Affiliated Hospital of Zhejiang University Medical College

Original title: EPCAM-Targeted Car-T Cell Therapy in Patients with Advanced Colorectal and Gastric Cancers

Gynecologic Oncology

9. Specialty: mini oral session 1: gynaeCological Cancers

Title: Cyli Mippitive+Bevarzab the treatment of recurrence/persistent ovarian transparent cell carcinoma (INOVA): a multi -center, single -arm, phase II clinical trial

Summary number: 522MO

Reporter: Gao Qinglei Huazhong University of Science and Technology Tongji Medical College Tongji Hospital

Original title: Preliminary Results of Sintilimab (SIN)+Bevacizumab (Bev) in ReCurrent/Persistent Ovarian Clear Cell CarCinoma (Inova): A Multicenter, Single-RM, Phase II TRIAL TRIAL

sarcoma

10. Specialty: mini oral session: sarcoma

Title: Lenvetinib+Aili Blin to treat biomarkers related to the efficacy of smooth muscle sarcoma and liposarcoma

Summary number: 1492MO

Reporter: tom wei-wu chen China Taiwan Taiwan

Original title: Immune and Vascular Biomarkeers Associated with Effical and Mechanism of the Combination of Lenvatinib (L) And Eribulin (E) in Leiomyosarcoma (LMS) and Liposarcoma (LMS) and Liposarcoma (LMS)

Blood system tumor

11. Special: Mini Oral Session: Haematology Malignancies

Title: The clinical value of CTDNA in the new diagnosis permeated large B -cell lymphoma

Summary number: 624MO

Reporter: Tao Guan

Original title: RETROSPECTIVE Analysis of Clinical Value of CTDNA in Newly Diagnose Large B Cell Lymphoma12, Special: MINI ORALSESSION: HAEMATOLOGAL MALIGNCIES

Title: Pharoma -hydrochloride Liposycoplasia+Pen Menase Treatment NK/T cell lymphoma: a phase I/II clinical trial

Summary number: 625MO

Reporter: Huang Yunhong Hongguizhou Medical University Affiliated Hospital

Original title: Combination of Mitoxantrone Hydrochloride Liposome with PEGASPARGASE in Patients with EXTRANOD NK/T-CELL LYMPHOMA: A Phase I/II Clinical TRial

13. Specialty: mini oralsulation: haematology malignancies

Title: Obesib+R-chop

Summary number: 627mo

Reporter: mingyue Wang

Original title: Orelabrutinib Plus RCHOP for Previously Untreated Non-Germinal Center B-Cell-Like (GCB) Diffuse Large B-Cell Lymphoma (DLBCL) Patients with Extraanodal Disease

14. Specialty: mini oralsulation: haematology malignancies

Title: DASH CAR-T cells: a clinical pre-clinical study prepared in 48 hours

Summary number: 621MO

Reporter: haiying wang

Original title: Preclinical Study of Dash Car-T Cells Manufactured in 48 Hours.

15. Specialty: Proffered Paper Session: Haematology Malignancies

Title: LEMZOPARLIMAB (a anti -CD47 monoclonal antibody) combined with Azatidin to treat the preliminary clinical results of the new diagnosis of high -risk bone marrow hyperplasia syndrome

Summary number: 617o

Reporter: chunkang Chang

原标题：Lemzoparlimab, a Differentiated Anti-CD47 Monoclonal Antibody, in Combination with Azacitidine (AZA) in Patients with Newly Diagnosed Higher Risk Myelodysplastic Syndrome (HR-MDS): Initial Clinical Results

16. Specialty: Proffered Paper Session: Haematology Malignancies

Title: TRS005 (A Anti-CD20-MMAE ADC) treatment recurrence/difficulty cure B cells non-Hodgkin lymphoma phase I clinical research

Summary number: 618O

Reporter: Shi Yuankai Cancer Hospital of the Chinese Academy of Medical Sciences

原标题：A phase I study of TRS005, an anti-CD20-MMAE antibody-drug conjugate, in relapsed or refractory B-cell non-Hodgkin lymphomaA phase I study of TRS005, an anti-CD20-MMAE antibody-drug conjugate, in Relapset or Refractory B-Cell Non-Hodgkin Lymphoma

17. Specialty: Proffered Paper Session: Haematology Malignancies

Title: Anti-CD19 CAR-T cell therapy for PD-1 gene knockout on SHRNA Street

Summary number: 619o

Reporter: Cen Hong Guangxi Medical University Affiliated Cancer Hospital

Original title: Shrna-Mediated PD1 Gene KNOCK-DOWN Anti-CD19 CAR-T Cell Therapy for RelapSed/Refractory B-Cell Malignan Cies

Organization of this article: oolong tea

Editor in charge: Sweet

- END -